Plasma exposure (AUC and Cmax) to valdecoxib was increased (62% and 19%, respectively) when co- administered with fluconazole (predominantly a CYP2C9 inhibitor), indicating that the dose of parecoxib sodium should be reduced in those patients who are receiving fluconazole therapy.